Applying the Glycopyrronium Wipe to the Underarm
A single-use cloth delivers glycopyrronium solution directly onto skin.
- 2.4%: Dose per wipe (glycopyrronium cloth)
- Axilla: Application site (underarm skin)
- ~1h: Onset window (placeholder estimate)
- Daily: Frequency (once per day typical)
Wipe mechanics
Cloth transfers drug onto stratum corneum for absorption.
Blocking Muscarinic M3 Receptors on Sweat Glands
Glycopyrronium competitively binds M3 receptors on gland cells.
- M3: Receptor type (muscarinic subtype)
- Competitive: Binding mode (vs acetylcholine)
- Local: Selectivity (skin-limited target)
- ~2-4h: Peak binding (placeholder estimate)
Receptor pharmacology
Drug occupies receptor site, preventing ACh docking.
Interrupting the Local Acetylcholine Signal
Nerve-released acetylcholine can no longer activate blocked receptors.
- ACh: Neurotransmitter (acetylcholine)
- Sympathetic cholinergic: Pathway (innervates eccrine glands)
- Blocked: Signal outcome (no secretory trigger)
- ~24h: Duration (per application)
Signal pathway
Blocked receptor halts downstream secretory activation.
Reduced Sweat Gland Output at the Treated Site
Eccrine glands secrete less sweat once receptors stay blocked.
- ~30-50%: Sweat reduction (placeholder trial figure)
- Gravimetric: Measure (sweat weight test)
- Hours: Onset (gradual decline)
- ~1 day: Duration (per wipe use)
Output measurement
Sweat output declines as blockade level rises.
Localized and Systemic Anticholinergic Effects
Some drug reaches circulation, causing mild anticholinergic effects.
- Dry mouth: Common effect (most frequent report)
- Mydriasis risk: Eye effect (if contact occurs)
- Frequency: Risk driver (more uses raise risk)
- Mostly mild: Severity (placeholder summary)
Safety monitoring
Frequent use raises systemic anticholinergic exposure.
Higher weekly frequency increases side effect risk in this model.